Amicus Therapeutics, Inc. (FOLD) News

Amicus Therapeutics, Inc. (FOLD): $10.44

0.11 (-1.04%)

POWR Rating

Component Grades








Add FOLD to Watchlist
Sign Up

Industry: Biotech




#57 of 363

in industry

Filter FOLD News Items

FOLD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FOLD News Highlights

  • FOLD's 30 day story count now stands at 6.
  • Over the past 19 days, the trend for FOLD's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about FOLD are SMID, STEP and BIO.

Latest FOLD News From Around the Web

Below are the latest news stories about AMICUS THERAPEUTICS INC that investors may wish to consider to help them evaluate FOLD as an investment opportunity.

‘Time to Pull the Trigger,’ Says Morgan Stanley About These 2 Healthcare Stocks

It’s been a bountiful year for the stock market but that doesn’t mean there haven’t been laggards. The biotech industry, for example, has underperformed. While the Nasdaq Biotechnology Index (NBI) shows a 3% year-to-date gain, that is still some distance below the S&P 500’s 24% return. Therefore, with investor sentiment subdued, and some SMID-cap biotech firms still needing to raise capital against a challenging capital markets backdrop, Morgan Stanley’s Jeffrey Hung says the setup for SMID-cap

Yahoo | December 24, 2023

Amicus Therapeutics Inc's Chief Development Officer Sells Shares

On December 20, 2023, Jeff Castelli, Chief Development Officer of Amicus Therapeutics Inc (NASDAQ:FOLD), sold 19,154 shares of the company, according to a recent SEC Filing.

Yahoo | December 21, 2023

Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

BIO names longtime Amicus head John Crowley as new CEO

Crowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers.

Yahoo | December 5, 2023

Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO

Crowley to Step Down from Amicus Board of Directors in March 2024 and Become Amicus Chairman Emeritus Michael Raab, Current Lead Independent Director, to Become Chairman of Amicus Board of Directors PRINCETON, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and Chief Executive Officer of BIO, the Biotechnolo

Yahoo | December 5, 2023

He Designed Drugs to Save His Children. Now He’s Working to Save Biotech, Too.

John Crowley will become a top lobbyist for the industry as it confronts investor skepticism and regulatory challenges.

Yahoo | December 5, 2023

7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps

These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.

Alex Sirois on InvestorPlace | November 15, 2023

Amicus Therapeutics, Inc. (NASDAQ:FOLD): Are Analysts Optimistic?

We feel now is a pretty good time to analyse Amicus Therapeutics, Inc.'s ( NASDAQ:FOLD ) business as it appears the...

Yahoo | November 11, 2023

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call Transcript

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call Transcript November 8, 2023 Amicus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.07, expectations were $-0.08. Operator: Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Third Quarter 2023 Financial Results Conference Call and webcast. [Operator Instructions] As a reminder, this conference is being […]

Yahoo | November 10, 2023

Amicus' (FOLD) Q3 Loss Narrows, Galafold Sales View Updated

Amicus (FOLD) incurs a narrower-than-expected loss in the third quarter. However, revenues beat estimates. The company tightens Galafold revenue guidance for 2023.

Yahoo | November 9, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!